Objectives-To determine the safety of thrombolytic treatment in patients with central venous cannulation.
Methods-Complications in 56 consecu-
tive patients admitted between 1989 and 1992 with infarction and who had cannulation shortly before, or within 24 h of thrombolysis were studied. Results-Central venous access was achieved via the subclavian route in 52 patients, the internal jugular in three, and the supraclavicular in one. The main indications were for inotropic drugs in 15 patients, pacing in 17, amiodarone infusion in 19, and pressure monitoring in five. Minor haemorrhagic complications occurred in five patients. Two Central venous cannulation is frequently employed in the management of patients with acute myocardial infarction. Moreover, a significant number of myocardial reinfarctions requiring a repeated dose of thrombolytic agent occur in the first few days after the initial infarction.8 Some of these patients would have had recent central venous cannulation and be denied thrombolysis because of a perceived risk of severe bleeding. We studied a consecutive series of patients who had central venous cannulation shortly before or after thrombolytic treatment to determine the safety of thrombolysis in association with central venous cannulation.
Patients and methods

PATIENTS
All patients admitted to the coronary care unit at York District Hospital between 1989 and 1992 who underwent central line insertion shortly before or within 24 h of thrombolytic treatment were included in the study. The study comprised 56 patients of whom 35 were male and 21 female patients. Their mean (SD) age was 67 (9) years. The mean (SD) (range) age of the men was 66 (9) (44-82) years and of the women 68 (8) (50-81) years.
The patients were divided into four groups corresponding to the main indication for central venous cannulation: inotropic drugs, amiodarone, temporary transvenous cardiac pacing, and pressure monitoring. All venous cannulations were performed by either a senior house officer or registrar, qualified for between two and five years. Values are number of patients. *Dobutamine and dopamine. A chest x ray was performed after central venous cannulation in 37 patients. The x ray of two patients showed blunting of the costophrenic angle suggestive of a small pleural effusion. Both chest x rays also showed evidence of pulmonary venous congestion with upper lobe diversion.
HAEMORRHAGIC COMPLICATIONS
Serial haemoglobin measurement was performed when clinically indicated. Minor bleeding complications occurred in five patients, all of whom had suffered inferior myocardial infarction. Table 5 Two further patients developed hypotension after venous cannulation. A 65 year old man (patient B) with a history of three previous myocardial infarctions suffered a further anteroseptal infarction and was treated with streptokinase. He was receiving longterm dipyridamole treatment. A subclavian venous line was inserted (8&25 h after starting streptokinase) for amiodarone, dobutamine, and dopamine infusion after cardiac arrest with ventricular fibrillation and severe pulmonary oedema post-arrest. His blood pressure decreased from a post-arrest measurement of 110/60 mm Hg to 50/35 mm Hg after venous cannulation. He died 90 min after cannulation. A 73 year old man (patient C) treated with streptokinase for inferior infarction developed complete heart block requiring temporary pacing. This was attempted without success from the right subclavian approach (3 h after starting streptokinase) and was inserted through the left subclavian vein. The patient had continuous bleeding and a large bruise on the right puncture site. He became hypotensive (blood pressure decreased from 100/60 mm Hg to 55/40 mm Hg) with loss of consciousness 4 h after venous cannulation. He died 16-5 h after the procedure. Both patients had a postprocedural chest x ray with no evidence of effusion. Cardiac failure was the likely cause of hypotension.
MORTALITY
Fourteen patients (25%) died within three days of admission. Twelve (86%) of these patients were in the inotropic or pressure monitoring groups. Mortality in these two groups was significantly higher than in the amiodarone (y2 = 10-8, P < 0-01) and pacing groups (X2 = 9.55, P < 0 01) in which one patient of each group died. Three further patients in the amiodarone and two in the inotropic group died of worsening cardiac failure by day 7.
Discussion
Central venous cannulation to facilitate drug administration, pressure monitoring, or temporary transvenous pacing is not uncommon in the setting of acute myocardial infarction. It does, however, present the clinician with an additional potential hazard to consider when weighing up the relative risks and benefits of thrombolytic treatment in a patient with infarction and a central line already inserted. Some authorities regard even one unsuccessful attempt at central line placement as an important contraindication to thrombolysis.67
There are, however, few data available to support this practice. The results of this study suggest that central venous cannulation is associated with a low incidence of significant bleeding complications in the presence of thrombolysis.
We included only patients who received central venous cannulation within 24 h of thrombolytic treatment because fibrinogen levels are known to be reduced and patients are at increased risk of haemorrhage during that time interval.'0 11 Major haemorrhagic complications directly attributable to central venepuncture possibly occurred in one patient. Even then patient A was already in significant cardiac failure before venous cannulation and cardiogenic shock was equally likely to have been the cause of hypotension. Unfortunately, this patient did not have a post-cannulation chest x ray and a haemothorax could not be confidently excluded. Patients B and C were in significant cardiac failure before central venous cannulation. The cause of hypotension was likely to be cardiac failure as significant bleeding would have been demonstrated in the post-cannulation chest x ray.
Most patients with congestive cardiac failure and significant hypotension were in the inotropic group. The mortality in these patients would be expected to be high. This is the case in our patients with a three day mortality of 60%. We chose to examine three day mortality because haemorrhagic complications are unlikely to be the main cause of death after this time. The seven day mortality is also listed in Our results suggest that thrombolytic treatment in patients with central venous cannulation is associated with a low incidence of important bleeding complications. We conclude that similar to cardiopulmonary resuscitation,'3 '4 central venous cannulation is not a clear contraindication to thrombolytic treatment. It would seem prudent, however, to use the femoral, jugular, or brachial veins'5 16 for cannulation of patients undergoing thrombolysis provided that appropriate training in the use of these routes is undertaken.
